Search Results: Treatment + Endometrial Cancer (7 results)
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.
Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced cancers
This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Testing Immunotherapy Treatments for Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer
Treatment
Treatment study for people with endometrial cancer that has returned
This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.
Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)
https://www.facingourrisk.org/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum
Treatment
Advanced endometrial cancer
This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
104 results
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT ID: NCT04196257 (https://clinicaltrials.gov/study/NCT04196257)
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT ID: NCT05592626 (https://clinicaltrials.gov/study/NCT05592626)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://clinicaltrials.gov/study/NCT04319757)
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
NCT ID: NCT04590326 (https://clinicaltrials.gov/study/NCT04590326)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
NCT ID: NCT03876860 (https://clinicaltrials.gov/study/NCT03876860)
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
NCT ID: NCT04104776 (https://clinicaltrials.gov/study/NCT04104776)
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT ID: NCT03065062 (https://clinicaltrials.gov/study/NCT03065062)
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT ID: NCT04514692 (https://clinicaltrials.gov/study/NCT04514692)
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05797831 (https://clinicaltrials.gov/study/NCT05797831)
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
NCT ID: NCT04569773 (https://clinicaltrials.gov/study/NCT04569773)
Genetic Testing in African Americans
NCT ID: NCT05591131 (https://clinicaltrials.gov/study/NCT05591131)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT ID: NCT06253494 (https://clinicaltrials.gov/study/NCT06253494)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://clinicaltrials.gov/study/NCT03682289)
Bariatric Education for Women With Obesity and Endometrial Cancer
NCT ID: NCT05396794 (https://clinicaltrials.gov/study/NCT05396794)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://clinicaltrials.gov/study/NCT05819892)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://clinicaltrials.gov/study/NCT05887492)
Mindfulness in Endometrial and Cervical Cancer
NCT ID: NCT04512144 (https://clinicaltrials.gov/study/NCT04512144)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://clinicaltrials.gov/study/NCT02632448)
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://clinicaltrials.gov/study/NCT05990426)
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
NCT ID: NCT05230186 (https://clinicaltrials.gov/study/NCT05230186)
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT ID: NCT05646316 (https://clinicaltrials.gov/study/NCT05646316)
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT ID: NCT06132958 (https://clinicaltrials.gov/study/NCT06132958)
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT ID: NCT05548296 (https://clinicaltrials.gov/study/NCT05548296)
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT ID: NCT05051722 (https://clinicaltrials.gov/study/NCT05051722)
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT ID: NCT02611024 (https://clinicaltrials.gov/study/NCT02611024)
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT ID: NCT04576104 (https://clinicaltrials.gov/study/NCT04576104)
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://clinicaltrials.gov/study/NCT05691010)
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT ID: NCT02628067 (https://clinicaltrials.gov/study/NCT02628067)
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT ID: NCT05523440 (https://clinicaltrials.gov/study/NCT05523440)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT ID: NCT05139368 (https://clinicaltrials.gov/study/NCT05139368)
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT ID: NCT03564340 (https://clinicaltrials.gov/study/NCT03564340)
Pilot Window of Opportunity Trial (POET)
NCT ID: NCT06129604 (https://clinicaltrials.gov/study/NCT06129604)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://clinicaltrials.gov/study/NCT04644068)
Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://clinicaltrials.gov/study/NCT05712668)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT ID: NCT05691504 (https://clinicaltrials.gov/study/NCT05691504)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://clinicaltrials.gov/study/NCT05039801)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://clinicaltrials.gov/study/NCT05112601)
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT ID: NCT05997017 (https://clinicaltrials.gov/study/NCT05997017)
(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://clinicaltrials.gov/study/NCT05252416)
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
NCT ID: NCT06388018 (https://clinicaltrials.gov/study/NCT06388018)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://clinicaltrials.gov/study/NCT04851119)
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://clinicaltrials.gov/study/NCT04997096)
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications
NCT ID: NCT05827614 (https://clinicaltrials.gov/study/NCT05827614)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT ID: NCT04839614 (https://clinicaltrials.gov/study/NCT04839614)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT ID: NCT00005095 (https://clinicaltrials.gov/study/NCT00005095)
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT ID: NCT05036681 (https://clinicaltrials.gov/study/NCT05036681)
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT ID: NCT04291612 (https://clinicaltrials.gov/study/NCT04291612)
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://clinicaltrials.gov/study/NCT05603910)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://clinicaltrials.gov/study/NCT06270706)
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
NCT ID: NCT04604613 (https://clinicaltrials.gov/study/NCT04604613)
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT ID: NCT06036836 (https://clinicaltrials.gov/study/NCT06036836)
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://clinicaltrials.gov/study/NCT06257264)
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT ID: NCT05500508 (https://clinicaltrials.gov/study/NCT05500508)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT ID: NCT03968406 (https://clinicaltrials.gov/study/NCT03968406)
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT ID: NCT04586959 (https://clinicaltrials.gov/study/NCT04586959)
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT ID: NCT04044859 (https://clinicaltrials.gov/study/NCT04044859)
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT ID: NCT04527900 (https://clinicaltrials.gov/study/NCT04527900)
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://clinicaltrials.gov/study/NCT04469764)
Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT ID: NCT04458402 (https://clinicaltrials.gov/study/NCT04458402)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT ID: NCT02922764 (https://clinicaltrials.gov/study/NCT02922764)
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://clinicaltrials.gov/study/NCT04925284)
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT ID: NCT05572684 (https://clinicaltrials.gov/study/NCT05572684)
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT05950464 (https://clinicaltrials.gov/study/NCT05950464)
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT ID: NCT04080284 (https://clinicaltrials.gov/study/NCT04080284)
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT ID: NCT05559879 (https://clinicaltrials.gov/study/NCT05559879)
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers
NCT ID: NCT05049538 (https://clinicaltrials.gov/study/NCT05049538)
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT ID: NCT03932409 (https://clinicaltrials.gov/study/NCT03932409)
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT ID: NCT04486352 (https://clinicaltrials.gov/study/NCT04486352)
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT ID: NCT05154487 (https://clinicaltrials.gov/study/NCT05154487)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://clinicaltrials.gov/study/NCT04300556)
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT ID: NCT06096688 (https://clinicaltrials.gov/study/NCT06096688)
Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://clinicaltrials.gov/study/NCT03785288)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://clinicaltrials.gov/study/NCT04704661)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554328 (https://clinicaltrials.gov/study/NCT05554328)
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT ID: NCT04567771 (https://clinicaltrials.gov/study/NCT04567771)
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT ID: NCT05542407 (https://clinicaltrials.gov/study/NCT05542407)
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT ID: NCT03422198 (https://clinicaltrials.gov/study/NCT03422198)
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT ID: NCT05538897 (https://clinicaltrials.gov/study/NCT05538897)
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
NCT ID: NCT04008797 (https://clinicaltrials.gov/study/NCT04008797)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://clinicaltrials.gov/study/NCT05489211)
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT ID: NCT04386993 (https://clinicaltrials.gov/study/NCT04386993)
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT ID: NCT03955978 (https://clinicaltrials.gov/study/NCT03955978)
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT06172478 (https://clinicaltrials.gov/study/NCT06172478)
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT ID: NCT05758688 (https://clinicaltrials.gov/study/NCT05758688)
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT ID: NCT05705505 (https://clinicaltrials.gov/study/NCT05705505)
Study of ART0380 in Patients With Biologically Selected Solid Tumors
NCT ID: NCT05798611 (https://clinicaltrials.gov/study/NCT05798611)
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer
NCT ID: NCT03675893 (https://clinicaltrials.gov/study/NCT03675893)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT ID: NCT05655598 (https://clinicaltrials.gov/study/NCT05655598)
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://clinicaltrials.gov/study/NCT04683653)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://clinicaltrials.gov/study/NCT05277051)
Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT ID: NCT04570553 (https://clinicaltrials.gov/study/NCT04570553)
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05761951 (https://clinicaltrials.gov/study/NCT05761951)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.